Godavari Biorefineries Limited (GBL), a leading ethanol producer and a pioneer in bio-based specialty chemicals in India, announced strong financial results for the third quarter of FY26, reflecting higher profitability, improved margins and steady progress in strategic initiatives. For the quarter ended Q3 FY26, the company recorded total income of ₹461.9 crore compared with ₹450.8 crore in the same period last year. EBITDA rose 13.8 percent year-on-year to ₹45.1 crore, while EBITDA margin improved to 9.8 percent from 8.8 percent a year earlier. Profit before tax, excluding exceptional items, increased sharply to ₹21.4 crore, up 152.2 percent year-on-year.
During the first nine months of FY26, GBL reported total income of ₹1,430.2 crore and EBITDA of ₹47.2 crore, compared with a loss of ₹1.4 crore in the corresponding period last year. Loss before tax, excluding exceptional items, narrowed significantly to ₹31.2 crore from ₹97.3 crore in 9M FY25.
The bio-based chemicals segment delivered strong growth, supported by rising demand for specialty chemicals. The sugar and cogeneration business also reported higher earnings during the quarter, while the ethanol segment remained stable. Specialty chemicals accounted for 62 percent of the bio-based chemicals mix in the first nine months of FY26, and the company expects this contribution to increase further as it expands its portfolio of high-value products.
Commenting on the results, Chairman and Managing Director Samir Somaiya said the company achieved a significant improvement in profitability during Q3 FY26 through operating efficiency and careful execution, along with a sharper focus on high-margin products. He noted that finance costs declined by 46 percent year-on-year, reflecting efforts to strengthen cash flows and support growth.
Mr Somaiya also highlighted key developments during the quarter, including the grant of a U.S. patent for a novel anti-cancer compound targeting triple-negative breast cancer, demonstrating the company’s focus on research-led innovation. Progress continued on the DME-to-CO₂ technology initiative, with pilot plant activities underway.
GBL recently partnered with Synthomer to develop bio-based alternatives to fossil-based monomers. Synthomer is commercialising bio-based butyl acrylate using GBL’s bio-based butanol, helping accelerate the adoption of sustainable raw materials across industries.
The company’s consumer brand, Jivana, crossed ₹100 crore in revenue during the first nine months of FY26, marking steady growth in the retail segment. GBL’s fungible grain-based ethanol capacity is expected to be commissioned in Q1 FY27, positioning the company to benefit from the expansion of the ethanol blending programme and rising demand for maize-based ethanol.
With continued investment in technology, capacity optimisation and sustainability initiatives, Godavari Biorefineries aims to strengthen efficiency, manage seasonal fluctuations and expand its presence in bio-based specialty chemicals. The company believes these efforts will support long-term growth and value creation.
Godavari Biorefineries Limited is among the top ethanol manufacturers in India and a frontrunner in ethanol-based chemical production. The company’s diverse portfolio includes bio-based chemicals, sugar, rectified spirits, ethanol, multiple alcohol grades, and power. GBL is uniquely positioned in the Indian market with an extensive range of bio-based products such as MPO, natural 1,3-butylene glycol, ethyl vinyl ether, and others.
Source: themachinemaker.com
